(Q35023287)

5 August 2017

Targeting the Akt/mTOR pathway in Brca1-deficient cancers (English)

1 reference

5 August 2017

T Xiang

1

1 reference

5 August 2017

Y Jia

2

1 reference

5 August 2017

D Sherris

3

1 reference

5 August 2017

S Li

4

1 reference

5 August 2017

H Wang

5

1 reference

5 August 2017

D Lu

6

1 reference

5 August 2017

Q Yang

7

1 reference

5 August 2017

language of work or name

English

0 references

publication date

17 January 2011

1 reference

5 August 2017

1 reference

5 August 2017

30

1 reference

5 August 2017

2443-2450

1 reference

5 August 2017

21

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2010.603

5 August 2017

0 references

cites work

Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

mTOR and cancer: many loops in one pathway.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

Negative Regulation of AKT Activation by BRCA1

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

Defining the role of mTOR in cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

mTOR pathway as a target in tissue hypertrophy.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

mTOR and cancer: insights into a complex relationship

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

Current development of mTOR inhibitors as anticancer agents

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

Complexity of the TOR signaling network.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

The Akt-mTOR tango and its relevance to cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

Activation of AKT kinases in cancer: implications for therapeutic targeting

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

Lack of PTEN sequesters CHK1 and initiates genetic instability.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

Dysregulation of the TSC-mTOR pathway in human disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

BRCA1 and BRCA2: 1994 and beyond

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

High frequency of mutations of the PIK3CA gene in human cancers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

The many forks in FOXO's road

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

BRCA1-associated tumorigenesis: what have we learned from knockout mice?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

Tumorigenesis in mice carrying a truncating Brca1 mutation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

Analysis of radon-associated squamous cell carcinomas of the lung for a p53 gene hotspot mutation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107712

Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer

8 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.603

The pharmacology of mTOR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.603

AKT activation predicts outcome in breast cancer patients treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.603

Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.603

Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.603

Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.603

Analysis of loss of heterozygosity and immunohistochemistry in BRCA1 gene in sporadic breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.603

Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.603

Expression of estrogen receptor-alpha and Ki67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21242970

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/ONC.2010.603

1 reference

5 August 2017

1 reference

5 August 2017

1 reference